Document:

Exhibit

AMENDMENT NO. 1
TO THE
SUPPLY AGREEMENT
THIS AMENDMENT NO. 1 TO THE SUPPLY AGREEMENT (this “Amendment”) is dated as of June 30, 2016, by and among Impax Laboratories, Inc., a Delaware corporation (“Buyer”), Actavis Elizabeth LLC, a Delaware limited liability company (“Actavis Elizabeth”), Actavis Group PTC Ehf., an Iceland einkahlutafelag (“Actavis PTC”), Actavis Holdco US, Inc., a Delaware corporation (“Actavis Holdco”), Actavis LLC, a Delaware limited liability company (“Actavis LLC”), Actavis Mid Atlantic LLC, a Delaware limited liability company (“Actavis Mid Atlantic”), Actavis Pharma, Inc., a Delaware corporation (“Actavis Pharma”), Actavis South Atlantic LLC, a Delaware limited liability company (“Actavis South Atlantic”), Andrx LLC, a Delaware limited liability company (“Andrx”), Breath Ltd., a United Kingdom private limited company (“Breath”), The Rugby Group, Inc., a New York corporation (“Rugby”), and Watson Laboratories, Inc., a Nevada corporation (“Watson” and, together with Actavis Elizabeth, Actavis PTC, Actavis Holdco, Actavis LLC, Actavis Mid Atlantic, Actavis Pharma, Actavis South Atlantic, Andrx, Breath and Rugby, each a “Manufacturer” and, collectively, the “Manufacturers”).
WITNESSETH:
WHEREAS, Buyer and the Manufacturers executed that certain Supply Agreement, dated June 20, 2016 (as amended, restated, waived or otherwise modified, the “Supply Agreement”); and
WHEREAS, the Parties have agreed to amend certain terms of the Supply Agreement.
NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:
1.Definitions.  Any capitalized term used in this Amendment shall have the meaning designated for the capitalized term in the Supply Agreement unless otherwise defined in this Amendment.  The term “Supply Agreement” used in the Supply Agreement shall hereafter refer to the Supply Agreement, as amended by this Amendment.
2.     Amendment of the Supply Agreement.  The Supply Agreement is hereby amended as follows (with deleted text shown as stricken and new text shown as double underlined):
(a)    The following terms are hereby added to Section 1.1 of the Supply Agreement:
““Cure Period” means [****] following Manufacturer’s receipt of notice from Buyer of a Supply Failure.”

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.  Confidential treatment has been requested with respect to the omitted portions.

““Customer” means any third party who purchases the Supply Product from the Buyer pursuant to a written agreement between the Buyer and such third party.”  
““Customer Penalties” means the aggregate penalties the Buyer incurs from its Customers, directly related to actual worth of the quantities of Supply Products subject to the applicable Supply Failure (which quantities shall not exceed [****] supply of the applicable Supply Products) as evidenced by written records, as a result of the Manufacturer’s Supply Failure, which amount generally represents [****].”  
“Wholesale Acquisition Cost” means, with respect to a Supply Product, [****].”
(b)    Section 7.2(a) of the Supply Agreement is hereby amended in its entirety to read as follows:
 “(a) [reserved]”
(c)    Section 7.2(b) of the Supply Agreement is hereby amended in its entirety to read as follows:
 “(b) any Manufacturer, on the one hand, or the Buyer, on the other hand, fails to cure any non-compliance with any of the terms and conditions hereof within the time period specified in any prior written notice (which will be at least [****]) delivered to the non-compliant Party by another Party; provided; however, that the Manufacturers shall be permitted to terminate under this Section 7.2(b) [****] prior written notice to the FTC only for the Buyer’s failure to pay amounts due to the Manufacturers pursuant to this Supply Agreement and not disputed in good faith by Buyer (it being understood that any amounts due for Supply Product rejected pursuant to Section 5.3 shall be deemed to be disputed in good faith) unless the FTC Staff objects to such termination in writing to the Manufacturer within [****] of the receipt of such notice to the FTC, in which case Manufacturer shall not be permitted to terminate and shall continue to supply under the terms and conditions hereof, but Manufacturer may require the Buyer to place any disputed amounts due into an escrow account until such time as an agreement over these amounts between the Manufacturer and the Buyer is reached or adjudicated; or”
(d)    Section 10.5 of the Supply Agreement is hereby amended and restated in its entirety to read as follows:
“(a)    In no event shall any Party be liable by reason of any breach of any representation, warranty, condition or other term of this Supply Agreement or any duty of common law, for any consequential, special, indirect, or incidental or punitive loss or damage (whether for loss of current or future profits, loss of enterprise value or otherwise), and all Parties agree that they shall not make any such claim; provided, however, that the foregoing does not limit any of the obligations or liability of (i) any Party or its Affiliates under Sections 10.1 and 10.2 with respect to (1) claims for 

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.  Confidential treatment has been requested with respect to the omitted portions.

indemnity of unrelated third parties, (2) liability arising from fraud of a Party or its Affiliates and (3) with respect to Manufacturer’s breach of its obligations pursuant to Section 3.2 and Section 5.3, liability arising from fraud, intentional breach or willful misconduct of a Party or its Affiliates or (ii) a Manufacturer for a Supply Failure due to the gross negligence of such Manufacturer; provided however, solely with respect to clause (ii) that Manufacturer shall only be subject to liability for consequential, special, indirect or incidental or punitive loss or damage where (A) the Supply Failure is the result of Manufacturer’s fraud, willful misconduct, or gross negligence; or (B) the Supply Failure is the result of the Manufacturer’s negligence and Manufacturer has not used its commercially reasonable best efforts to cure the Supply Failure during the Cure Period; provided further that in no event shall Manufacturer be liable with respect to any customer penalties due to any such Supply Failure under (A) or (B), above, other than the Customer Penalties.
(b)    Notwithstanding any other provision of this Supply Agreement, in the event that the Buyer asserts or claims that any Manufacturer has breached any of its obligations hereunder or that any Manufacturer is liable pursuant to Section 10.1, such Manufacturer’s maximum liability under or in connection with (i)(A) any such claim herein, together with any such claim against any other Manufacturer pursuant to this Supply Agreement or under the Other Supply Agreement, asserted prior to [****] shall be limited to [****] and (ii)(B) any such claim herein, together with any such claim against any other Manufacturer pursuant to this Supply Agreement or under the Other Supply Agreement, asserted on or following [****] shall be limited to [****]; and (ii) any reimbursement of Customer Penalties in accordance with the terms herein shall not exceed [****] for all Supply Products supplied by the Manufacturer under this Supply Agreement and the Other Supply Agreements.”
3.    Miscellaneous.
(a)    Effectiveness of Amendment. This Amendment shall become effective upon the date hereof.  In the event of any inconsistency or conflict between the Supply Agreement and this Amendment, the terms, conditions and provisions of this Amendment shall govern and control.
(b)    General Provisions.  Article XII of the Supply Agreement shall apply to this Amendment, mutatis mutandis. 
*  *  *  *  *  *

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.  Confidential treatment has been requested with respect to the omitted portions.

IN WITNESS WHEREOF, this Amendment has been executed and delivered by the parties hereto effective as of the date first above written.

WATSON LABORATORIES, INC.
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President    
ACTAVIS HOLDCO US, INC.
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President    
THE RUGBY GROUP, INC.
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            
ANDRX LLC
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            
ACTAVIS ELIZABETH LLC
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            

[Signature Page to Impax-Allergan Supply Agreement Amendment]

ACTAVIS SOUTH ATLANTIC LLC
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            
ACTAVIS MID ATLANTIC LLC
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            
ACTAVIS PHARMA, INC.
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            
 

ACTAVIS LLC
By: /s/ A. Robert D. Bailey    
Name: A. Robert D. Bailey    
Title: President            
 

ACTAVIS GROUP PTC ehf
By: /s/ Guojon Gustafsson    
Name: Guojon Gustafsson    
Title: Director    
 

[Signature Page to Impax-Allergan Supply Agreement Amendment]

By: /s/ Hafrun Frioriksdottir    
Name: Hafrun Frioriksdottir    
Title: Director    

 
By: /s/ Daniel Motto    
Name: Daniel Motto    
Title: Director                
BREATH LTD.
By: /s/ Sara Vincent    
Name: Sara Vincent    
Title: Director                

IMPAX LABORATORIES, INC.
By: /s/ G. Frederick Wilkinson    
Name: G. Frederick Wilkinson    
Title: President, Chief Executive Officer

 

[Signature Page to Impax-Allergan Supply Agreement Amendment]Exhibit 4.1

 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES
LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (I) A REGISTRATION
STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE WITH REGARD THERETO, OR (II)
AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS IS AVAILABLE IN CONNECTION WITH SUCH
OFFER, SALE OR TRANSFER.

 

AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF
RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED.

 

	Warrant to Purchase	 
	1,100,000 shares	Warrant Number No. 1

 

Warrant to Purchase American Depositary
Shares

of

Avadel Pharmaceuticals plc

 

THIS CERTIFIES that Breaking Stick Holdings, LLC or any subsequent
holder hereof (“Holder”) has the right to purchase from Avadel Pharmaceuticals plc, a public limited company incorporated
under the laws of Ireland (the “Company”), one million, one hundred thousand (1,100,000) American Depositary Shares
(“ADSs”) or Restricted ADSs (as defined below), as the case may be, each representing one Ordinary Share, nominal value
$0.01 per share (“Ordinary Shares”), which ADSs or Restricted ADSs, as the case may be, will be evidenced by American
Depositary Receipts (“ADRs”) or Restricted ADRs (as defined below), as the case may be, and will be issued pursuant
to the Deposit Agreement, dated as of January 3, 2017 (the “Deposit Agreement”), with the Bank of New York Mellon,
as Depositary, subject to adjustment as provided herein, at a price equal to the Exercise Price as defined in Section 3 below,
at any time during the Term (as defined below). To the extent the Warrant Shares (as defined below) issuable upon exercise of this
Warrant shall contain the restrictive legend substantially in the form set forth in Section 2(e)(i) in accordance with the terms
hereof, such Warrant Shares shall be in the form of “Restricted ADSs” (as defined below) evidenced by Restricted ADRs
(as defined below).

 

Each ADS and Restricted ADS shall represent one Ordinary Share,
and such ratio shall be deemed to be maintained for all purposes hereunder, and to the extent such ratio is not maintained, the
adjustments pursuant to Section 5 hereof shall be adjusted to take into account any such change to such ratio.

 

Holder agrees with the Company that this Warrant to Purchase
ADSs or Restricted ADSs of the Company (this “Warrant” or this “Agreement”) is issued and all rights hereunder
shall be held subject to all of the conditions, limitations and provisions set forth herein.

 

		1.	Date of Issuance and Term.

 

(a)          This
Warrant shall be deemed to be issued on March 13, 2012 (“Date of Issuance”) and reissued on January 1, 2017 (the “Reissuance
Date”). The term of this Warrant begins on the Date of Issuance and ends at 5:00 p.m., New York City time, on the date that
is six (6) years after the Date of Issuance (the “Term”). This Warrant was (i) issued in conjunction with that certain
Membership Interest Purchase Agreement by and among Flamel Technologies S.A. (predecessor of the Company) (the “Predecessor”),
Flamel US Holdings, Inc., Breaking Stick Holdings, LLC (formerly known as Eclat Holdings, LLC), and Eclat Pharmaceuticals, LLC
dated March 13, 2012 (the “Purchase Agreement”), the Registration Rights Agreement by and between the Predeccesor and
Breaking Stick Holdings, LLC dated March 13, 2012 (“Registration Rights Agreement”) and the Note Agreement (the “Note
Agreement”) by and among the Predeccesor, Flamel US Holdings, Inc. and Breaking Stick Holdings, LLC, dated March 13, 2012,
entered into in conjunction herewith, and (ii) reissued by the Company on the Reissuance Date in connection with the consummation
of the merger of the Predecessor with and into the Company, effected to change the jurisdiction of incorporation of the Predecessor
from France to Ireland.

 

     

     

    

  

(b)          Notwithstanding
anything herein to the contrary, the Company shall not issue to the Holder, and the Holder may not acquire, a number of ADSs or
Restricted ADSs upon exercise of this Warrant to the extent that, upon such exercise, the number of Ordinary Shares (including
through the ownership of ADSs or Restricted ADSs) then beneficially owned by the Holder and its Affiliates and any other persons
or entities whose beneficial ownership of Ordinary Shares (including through the ownership of ADSs or Restricted ADSs) would be
aggregated with the Holder’s for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (including
shares held by any “group” of which the Holder is a member, but excluding shares beneficially owned by virtue of the
ownership of securities or rights to acquire securities that have limitations on the right to convert, exercise or purchase similar
to the limitation set forth herein), would exceed 9.985% of the total number of Ordinary Shares then issued and outstanding (the
“9.985% Cap”); provided, however, that the 9.985% Cap shall not apply with respect to the issuance of ADSs or Restricted
ADSs pursuant to a Cashless Major Exercise (as defined below) in connection with a Major Transaction (as defined below) covered
by the provisions of Section 5(c)(i)(A) below in which the Company is not the surviving entity (a “Qualified Change of Control
Transaction”); and provided, further, that the 9.985% Cap shall only apply to the extent that the Ordinary Shares (and ADSs
or Restricted ADSs in respect of Ordinary Shares) are deemed to constitute “equity securities” pursuant to Rule 13d-1(i)
promulgated under the Exchange Act. For purposes hereof, “group” has the meaning set forth in Section 13(d) of the
Exchange Act and applicable regulations of the Securities and Exchange Commission (the “SEC”), and the percentage held
by the Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act. Upon the written
request of the Holder, the Company shall, within two (2) Trading Days, confirm orally and in writing to the Holder the number of
Ordinary Shares then outstanding. In the event that the Company is not permitted to issue Warrant Shares to the Holder pursuant
to this Warrant because of the provisions of this Section 1(b), the Company shall not be required to net cash settle or otherwise
make any cash payment to the Holder in lieu of such issuance; provided that this sentence shall not affect any separate obligation
hereunder that the Company may have at such time to the Holder.

 

		(c)	Definitions.

 

“Affiliate” means any person or entity that, directly
or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a person or entity,
as such terms are used in and construed under Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”).
With respect to a Holder of Warrants, any investment fund or managed account that is managed on a discretionary basis by the same
investment manager as such Holder will be deemed to be an Affiliate of such Holder.

 

“Holder” means Breaking Stick Holdings, LLC and
any transferee or assignee pursuant to the terms of this Warrant.

 

“Restricted ADR” means a certificated American Depositary
Receipt that includes the restrictive legend substantially in the form set forth in Section 2(e)(i), evidencing one or more restricted
American Depositary Shares (“Restricted ADSs”), with each Restricted ADS representing one Ordinary Share.

 

“Restricted ADR Depositary” means The Bank of New
York acting as depositary for the Restricted ADRs pursuant to an instruction letter between the Bank of New York and the Company,
and for the Shares acting as successor depositary for the Restricted ADRs.

 

“Transfer Agent” means the Company or any Person
the Company may, from time to time, appoint to serve as the Transfer Agent.

 

    2

     

    

  

		2.	Exercise; Redemption.

 

(a)          Manner
of Exercise. During the Term, this Warrant may be Exercised as to all or any lesser number of ADSs or Restricted ADSs covered
hereby (the “Warrant Shares” or the “Shares”) upon surrender of this Warrant, with the Exercise Form attached
hereto as Exhibit A-1 (the “Exercise Form”) duly completed and executed, together with the full Exercise Price
(as defined below, which may be satisfied by a Cash Exercise or a Cashless Exercise, as each is defined below) for each ADS or
Restricted ADS as to which this Warrant is Exercised, at the office of the Company, Block 10-1, Blanchardstown Corporate Park,
Ballycoolin, Dublin 15, Ireland; Phone: +353 1 485 1200, Fax: +353 1 526 1077, or at such other office or agency as the Company
may designate in writing, by express mail or, so long as the original Exercise Form and Warrant is sent by the Holder no later
than the date of such facsimile, via facsimile or electronic mail (such surrender and payment of the Exercise Price hereinafter
called the “Exercise” of this Warrant).

 

(b)          Date
of Exercise. The “Date of Exercise” of the Warrant shall be defined as the date that the Exercise Form attached
hereto as Exhibit A-1, completed and executed, is sent by facsimile or electronic mail to the Company and the Transfer Agent
and the payment of the Exercise Price to the Company is satisfied (if the Exercise is a Cash Exercise), provided that the original
Warrant and Exercise Form are received by the Company as soon as practicable thereafter. Alternatively, the Date of Exercise shall
be defined as the date the original Exercise Form is received by the Company, and the Exercise Price is satisfied (if the Exercise
is a Cash Exercise), if Holder has not sent advance notice by facsimile or electronic mail. Upon delivery of the Exercise Form
to the Company by facsimile or electronic mail or otherwise and receipt of the Exercise Price is satisfied (if the Exercise is
a Cash Exercise), the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares
with respect to which this Warrant has been Exercised, irrespective of the date such Warrant Shares are credited to the Holder’s
Depository Trust Company (“DTC”) account or the date of delivery of the certificates evidencing such Warrant Shares,
as the case may be; provided, however, that in the event of a Cashless Major Exercise in respect of a Qualified Change of Control
Transaction, the Holder shall be deemed to have become the holder of record of the shares issuable upon such exercise immediately
prior to the consummation of such Qualified Change of Control Transaction.

 

(c)          Delivery
of ADSs or Restricted ADSs Upon Exercise. (i) Within five (5) business days after any Date of Exercise, or in the case of a
Cashless Major Exercise or a Cashless Default Exercise (each as defined in Section 5(c) below), within the period provided in Section
5(c)(iv) or Section 3(c), as applicable (the “Delivery Period”), the Company shall (i) cause Ordinary Shares representing
the number of Exercise Shares to be issued and deposited with the Depositary or the Restricted ADR Depositary, as applicable and
(ii) use commercially reasonable best efforts to cause ADSs or Restricted ADSs , as the case may be, representing the number of
shares purchased hereunder upon exercise (collectively, “Exercise Shares”) to be transmitted and delivered to the Holder
in accordance with the terms hereof. Upon the Exercise of this Warrant or any part hereof, the Company shall, at its own cost and
expense, use its commercially reasonable best efforts, including obtaining and delivering an opinion of counsel, to assure that
the requisite certificates shall be issued in the name of Holder (or its nominee) or such other persons as designated by Holder
and in such denominations to be specified at such Exercise representing the number of ADSs issuable upon such Exercise. Without
limiting the foregoing, during the Delivery Period, the Company shall deposit the corresponding number of Ordinary Shares underlying
the ADSs or Restricted ADSs pursuant to the Deposit Agreement and pay by wire transfer to the Depositary’s account, or, if
applicable the Restricted ADR Depositary’s account, all ADS and Restricted ADS issuance fees provided for under the Deposit
Agreement, together with all applicable taxes and expenses otherwise payable under the terms of the Deposit Agreement for the deposit
of Ordinary Shares and issuance of ADSs or Restricted ADSs (including, without limitation, confirmation that any Irish stock transfer
taxes in respect of such deposit (if any) have been paid by the Company), and the Company shall otherwise comply with and use commercially
reasonable best efforts to cause any other necessary party to comply with all the terms of the Deposit Agreement. The Company shall
pay, or cause to be paid any and all taxes, fees and charges (excluding any taxes on the income of the Holder) which may be payable
with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant; provided, that the Company shall not
be required to pay any tax that may be payable in respect of any transfer involved in the issuance and delivery of any such certificate
upon exercise in a name other than that of the Holder of this Warrant or any holder of equity interests in the Holder and the Company
shall not be required to issue or deliver such certificates unless or until the person or persons requesting the issuance thereof
shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax
has been paid. Appropriate and equitable adjustment to the terms and provisions of this Warrant shall be made in the event of any
change to the ratio of ADSs and Restricted ADSs to Ordinary Shares represented thereby. The Company warrants that no instructions
contrary to these instructions have been or will be given to the Depositary or the Transfer Agent and that, unless waived by the
Holder, this Warrant and the Exercise Shares will be free-trading, and freely transferable, and will not contain a legend restricting
the resale or transferability of the Exercise Shares if the Unrestricted Conditions (as defined below) are met.

 

    3

     

    

  

(ii)         In
the event that the Company determines to cease causing Ordinary Shares to be represented by ADSs, then all references to ADRs and
Restricted ADRs, or ADSs or Restricted ADSs, shall be deemed references to whatever shares are then issued by the Company and all
other provisions of this Agreement shall be equitably adjusted by the parties hereto to the extent necessary or appropriate to
reflect the ceasing of the Ordinary Shares to be represented by ADSs.

 

(d)          Delivery
Failure. In addition to any other remedies which may be available to the Holder, in the event that the Company fails for any
reason to effect delivery of the Exercise Shares to the Holder or to effect the issuance and deposit of the corresponding Ordinary
Shares to the Depositary or the Restricted ADR Depositary, as applicable, by the end of the Delivery Period (a “Delivery
Failure”), the Holder will be entitled to revoke all or part of the relevant Exercise Form by delivery of a notice to such
effect to the Company and the Transfer Agent, whereupon the Company and the Holder shall each be restored to their respective positions
immediately prior to the delivery of such notice, except that the liquidated damages described herein shall be payable through
the date notice of revocation or rescission is given to the Company.

 

		(e)	Legends.

 

(i)          Restrictive
Legend. The Holder understands that, until such time as the sale of this Warrant, the Exercise Shares and the Failure Payment
Shares have been registered under the Securities Act (including to the extent contemplated by the Registration Rights Agreement)
or this Warrant, the Exercise Shares and the Failure Payment Shares, as applicable, otherwise may be sold pursuant to Rule 144
under the Securities Act or an exemption from registration under the Securities Act without any restriction as to the number of
securities as of a particular date that can then be immediately sold, this Warrant, the Exercise Shares and the Failure Payment
Shares, as applicable, may bear a restrictive legend in substantially the following form (and a stop-transfer order may be placed
against transfer of the certificates for such securities):

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY
NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION,
PURSUANT TO RULES 144 OR 144A UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION
OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE, SUBJECT TO DELIVERY OF AN OPINION, AS PROVIDED IN THE
WARRANT ISSUED AS OF MARCH 13, 2012 BY THE COMPANY.”

 

“THE SALE, TRANSFER, ASSIGNMENT, PLEDGE, HYPOTHECATION
OR OTHER DISPOSITION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION
RIGHTS AGREEMENT DATED AS OF MARCH 13, 2012, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING
SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE
TO THE SECRETARY OF THE COMPANY.”

 

    4

     

    

  

(ii)           Removal
of Restrictive Legends. The Company shall use commercially reasonable best efforts to cause the Depositary to remove any legend
restricting the transfer (including the legend set forth above in subsection 2(e)(i)) of this Warrant and the certificates (or
electronic transfer) evidencing the Exercise Shares and the Failure Payment Shares, as applicable: (A) while a registration statement
(including a Registration Statement, as defined in the Registration Rights Agreement) covering the sale or resale of such security
is effective under the Securities Act, or (B) following any sale of such Warrant, Exercise Shares and/or Failure Payment Shares
pursuant to Rule 144 of the Securities Act, or (C) if such Warrant, Exercise Shares and/or Failure Payment Shares are eligible
for sale under Rule 144(b)(1) of the Securities Act, or (D) if such legend is not required under applicable requirements of the
Securities Act (including judicial interpretations and pronouncements issued by the staff of the SEC) (collectively, the “Unrestricted
Conditions”). If the Unrestricted Conditions are met at the time of issuance of the Exercise Shares or the Failure Payment
Shares, then the Company shall use commercially reasonable best efforts to cause the Depositary to issue such Exercise Shares or
Failure Payment Shares, as applicable, free of all legends. The Company agrees that following such time as the Unrestricted Conditions
are met or such legend is otherwise no longer required under this Section 2(e), it will, no later than three (3) Trading Days following
the delivery by the Holder to the Company or the Transfer Agent of a certificate representing Exercise Shares and/or Failure Payment
Shares, as applicable, issued with a restrictive legend, use its commercially reasonable best efforts to cause the Depositary to
deliver to such Holder a certificate (or electronic transfer) representing such shares that is free from all restrictive and other
legends. The Company shall cause its counsel to issue a legal opinion to the Transfer Agent promptly after the Effective Date if
required by the Transfer Agent to effect the issuance of the Exercise Shares or the Failure Payment Shares, as applicable, without
a restrictive legend or removal of the legend hereunder. For purposes hereof, “Effective Date” shall mean the date
that the Registration Statement that the Company is required to file pursuant to the Registration Rights Agreement has been declared
effective by the SEC, which the Company hereby acknowledges and agrees occurred on October 1, 2012. The Company further hereby
acknowledges and agrees that the reissuance of the Warrant on the Reissuance Date did not interrupt or otherwise affect the holding
period of this Warrant for purposes of Rule 144 under the Securities Act.

 

(iii)          Removal
of Legends from Restricted ADRs. A Restricted ADS may be surrendered by the holder thereof to the Restricted ADR Depositary
for cancellation, and the Depositary shall issue and deliver an unrestricted ADR with respect to the Restricted ADS formerly represented
by such Restricted ADR, provided that such Restricted ADR is surrendered in connection with a transfer of the related ADS and provided
further that (a) one of the Unrestricted Conditions is met and (b) the deposit of such Ordinary Shares in an unrestricted depositary
facility and the sale of any related ADSs by that person are not otherwise restricted under the Securities Act. If the removal
of the legend, as described in the preceding sentence, is effected in connection with the transfer of the Restricted ADS pursuant
to Rule 144 under the Securities Act, the Holder shall, if requested by the Company or the Restricted ADR Depositary, deliver an
opinion of counsel addressed and reasonably satisfactory to the requesting party. Any reasonable fees (with respect to the Restricted
ADR Depositary, the Depositary or otherwise) associated with the issuance of such opinion or the removal of the legend shall be
borne by the Holder. In the event that only a portion of the Restricted ADSs represented by a Restricted ADR have been transferred
by the holder thereof, the Restricted ADR Depositary shall issue a Restricted ADR that includes the legend in Section 2(e)(i) above
with respect to the Restricted ADSs that continue to be held by such holder. While a Registration Statement is effective or at
such earlier time as a legend is no longer required for the Restricted ADRs, the Company will cooperate with the Restricted ADR
Depositary, and shall use its commercially reasonable efforts, to facilitate the issuance of unrestricted ADRs as described above
no later than three (3) Trading Days following the delivery by such Holder to the Restricted ADR Depositary (with notice to the
Company) of a Restricted ADR (endorsed or with applicable powers attached, signatures guaranteed, and otherwise in form necessary
to effect the reissuance and/or transfer and an opinion of counsel to the extent required by Section 8(b)) .

 

    5

     

    

 

(iv)          Sale
of Unlegended Shares. Holder agrees that the removal of the restrictive legend from any certificates representing securities
as set forth in Section 2(e) above is predicated upon the Company’s reliance that the Holder will sell, transfer, assign,
pledge, hypothecate or otherwise dispose of the Exercise Shares and/or any Failure Payment Shares, as applicable, pursuant to either
the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption
therefrom, and that if such securities are sold pursuant to a Registration Statement, they will be sold in compliance with the
plan of distribution set forth therein.

 

(f)           Cancellation
of Warrant. This Warrant shall be cancelled upon the full Exercise or redemption of this Warrant, and, as soon as practical
after the Date of Exercise, Holder shall be entitled to receive ADSs or Restricted ADSs for the number of shares purchased upon
such Exercise of this Warrant or cash for the portion of this Warrant subject to redemption, and if this Warrant is not Exercised
or redeemed in full, Holder shall be entitled to receive a new Warrant (containing terms identical to this Warrant) representing
any unexercised portion of this Warrant in addition to such ADSs or Restricted ADSs or cash payment, as the case may be. In the
event of a Major Transaction (as defined below) in which all ordinary shares of the Company are cancelled and/or converted or exchanged
into the right to receive cash and/or securities of Another Entity (as defined below), then, any portion of this Warrant that the
Holder has not elected to exercise or be redeemed pursuant to the terms of this Warrant prior to the consummation of such Major
Transaction (a “Share Conversion Major Transaction”), shall automatically and immediately be deemed to have been exercised
pursuant to a Cashless Exercise, immediately prior to the consummation of such Share Conversion Major Transaction, and this Warrant
shall be deemed cancelled upon consummation of such Share Conversion Major Transaction.

 

(g)          Holder
of Record. Each person in whose name any Warrant for Warrant Shares is issued shall, for all purposes, be deemed to be the
Holder of record of such shares on the Date of Exercise of this Warrant, irrespective of the date of delivery of the Warrant Shares
purchased upon the Exercise of this Warrant.

 

(h)          Delivery
of Electronic Shares. In lieu of delivering physical certificates representing the ADSs or Restricted ADSs, as applicable,
issuable upon Exercise or legend removal, or representing Failure Payment Shares, provided the DTC Fast Automated Securities Transfer
(“FAST”) program is available with respect to the ADSs or Restricted ADSs, upon written request of the Holder, the
Company shall use its commercially reasonable best efforts to cause the ADSs or Restricted ADSs issuable upon Exercise to be electronically
transmitted to the Holder by crediting the account of the Holder’s prime broker with DTC through its Deposit/Withdrawal at
Custodian (DWAC) system. The time periods for delivery and penalties described herein shall apply to the electronic transmittals
described herein. Any delivery not effected by electronic transmission shall be effected by delivery of physical certificates.

 

(i)           Buy-In.
In addition to any other rights available to the Holder, if the Company fails to transmit to the Holder a certificate or certificates,
or electronic shares through DWAC, representing the Exercise Shares pursuant to an Exercise on or before the Delivery Period (other
than a failure caused by any incorrect or incomplete information provided by the Holder to the Company hereunder), and if after
such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage
firm otherwise purchases ADSs or Ordinary Shares to deliver in satisfaction of a sale by the Holder of Exercise Shares which the
Company was required to deliver to Holder upon such Exercise (a “Buy-In”), then the Company shall (1) pay in cash to
the Holder the amount by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the ADSs
or Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (A) the number of Exercise Shares that the Company
was required to deliver to the Holder in connection with the Exercise at issue times and (B) the price at which the sell order
giving rise to such purchase obligation was executed, and (2) at the option of the Holder, either reinstate the portion of the
Warrant and equivalent number of Exercise Shares for which such Exercise was not honored or deliver to the Holder the number of
ADSs or Restricted ADSs that would have been issued had the Company timely complied with its Exercise and delivery obligations
hereunder. For example, if the Holder purchases ADSs having a total purchase price of $11,000 to cover a Buy-In with respect to
an attempted Exercise to cover the sale of ADSs with an aggregate sale price giving rise to such purchase obligation of $10,000,
under clause (1) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall
provide the Company written notice, which notice will be within two Trading Days of the occurrence of the Buy-In, indicating the
amounts payable to the Holder in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested
by the Company. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing ADSs upon Exercise of the Warrant as required pursuant to the terms hereof.

 

    6

     

    

  

3.            Payment
of Warrant Exercise Price for Cash Exercise or Cashless Exercise; Cashless Major Exercise and Cashless Default Exercise.

 

(a)          Exercise
Price. The Exercise Price (“Exercise Price”) shall initially equal $11.00 per share, subject to adjustment pursuant
to the terms hereof, including but not limited to Sections 3(f) and 5 below.

 

Payment of the Exercise Price may be made by either of the following,
or a combination thereof, at the election of Holder:

 

(i)           Cash
Exercise: The Holder may exercise this Warrant in cash, bank or cashier’s check or wire transfer (a “Cash Exercise”);
or

 

(ii)          Cashless
Exercise: The Holder, at its option, may exercise this Warrant in a cashless exercise transaction, provided, however, that,
except as provided in Section 2(f) above, in the event that the Company has an effective registration statement under the Securities
Act covering the resale by the Holder of all Warrant Shares issuable upon such Cashless Exercise of this Warrant that the Holder
is then exercising, then the Holder shall not be permitted to exercise this Warrant as a Cashless Exercise under this Section 3(a)(ii)
with respect to the Warrant Shares issuable upon such exercise. In order to effect a Cashless Exercise, the Holder shall surrender
this Warrant at the principal office of the Company together with notice of cashless election, in which event the Company shall
issue to the Holder a number of ADSs or, if at the time of such exercise none of conditions listed in Sections 2(e)(ii)(B), (C)
or (D) have been met, Restricted ADSs, in each case, computed using the following formula (a “Cashless Exercise”):

 

X = Y (A–B)/A

 

where: X = the number of ADSs and Restricted ADSs to be issued
to Holder.

 

Y = the number of ADSs and Restricted ADSs for which
this Warrant is being Exercised or the number of ADSs and Restricted ADSs underlying the portion of this Warrant subject to redemption.

 

A = the Market Price of one (1) ADS, where “Market
Price,” as of any date, means the Volume Weighted Average Price (as defined herein) of the Company’s ADS during the
ten (10) consecutive Trading Day period immediately preceding the Date of Exercise.

 

B = the Exercise Price.

 

As used herein, the “Volume Weighted Average
Price” for any security as of any date means the volume weighted average sale price on The NASDAQ Global Market (“NASDAQ”)
as reported by, or based upon data reported by, Bloomberg Financial Markets or an equivalent, reliable reporting service mutually
acceptable to and hereafter designated by holders of a majority in interest of the Warrants and the Company (“Bloomberg”)
or, if NASDAQ is not the principal trading market for such security, the volume weighted average sale price of such security on
the principal securities exchange or trading market where such security is listed or traded as reported by Bloomberg, or, if no
volume weighted average sale price is reported for such security, then the last closing trade price of such security as reported
by Bloomberg, or, if no last closing trade price is reported for such security by Bloomberg, the average of the bid prices of any
market makers for such security that are listed in the over the counter market by the Financial Industry Regulatory Authority,
Inc. or in the “pink sheets” by the OTC Markets Group, Inc. If the Volume Weighted Average Price cannot be calculated
for such security on such date in the manner provided above, the volume weighted average price shall be the fair market value as
mutually determined by the Company and the Holders of a majority in interest of the Warrants being Exercised for which the calculation
of the volume weighted average price is required in order to determine the Exercise Price of such Warrants. “Trading Day”
shall mean any day on which the ADSs are traded for any period on NASDAQ, or on the principal securities exchange or other securities
market on which the ADSs are then being traded.

 

    7

     

    

  

In the case of the allotment and issue of Warrant Shares pursuant
to a Cashless Exercise, Cashless Major Exercise or Cashless Default Exercise, or of Failure Payment Shares, subject to complying
at all times with Irish law, the Company shall, if necessary, pay or cause the payment of at least the nominal value of the shares
so allotted and issued.

 

(b)          Cashless
Major Exercise. If the Holder, at its option, exercises this Warrant or any permissible portion thereof in a Cashless Major
Exercise pursuant to Section 5(c)(i) below, the Holder shall surrender this Warrant at the principal office of the Company together
with the Exercise Form indicating that the Holder is exercising this Warrant (or such permissible portion thereof) pursuant to
a Cashless Major Exercise, in which event the Company shall issue to the Holder a number of ADSs or Restricted ADSs, as applicable,
equal to the Black Scholes Value (as defined in Section 5(c)(iii) below) of the Warrant (or such applicable portion being exercised)
divided by the closing price of the ADSs on the principal securities exchange or other securities market on which the ADSs are
then traded on the Trading Day immediately preceding the date on which the applicable Major Transaction is consummated.

 

(c)          Cashless
Default Exercise. To the extent the Holder exercises this Warrant as a Cashless Default Exercise pursuant to Section 11(b)(i)
below, the Holder shall surrender this Warrant to the principal office of the Company together with the Exercise Form indicating
that the Holder is exercising this Warrant pursuant to a Cashless Default Exercise, in which event the Company shall issue to the
Holder, within five (5) Trading Days of the applicable Default Notice, a number of ADSs or Restricted ADSs, as applicable (which
shares shall be valued at the Volume Weighted Average Price for the five (5) Trading Days prior to the applicable Default Notice)
equal to the greater of (A) the Black-Scholes value (determined by use of the Black-Scholes Option Pricing Model using the criteria
set forth on Schedule I hereto) of the remaining unexercised portion of this Warrant on the date of such Default Notice and (B)
the Black-Scholes value (determined by use of the Black-Scholes Option Pricing Model using the criteria set forth on Schedule I
hereto) of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that the Exercise
Shares in respect of such Cashless Default Exercise are issued to the Holder.

 

(d)          Dispute
Resolution. In the case of a dispute as to the determination of the closing price or the Volume Weighted Average Price of the
Company’s ADSs or the arithmetic calculation of the Exercise Price, Market Price or any Major Transaction Warrant Early Termination
Price, the Company shall submit the disputed determinations or arithmetic calculations via facsimile within two (2) business days
of receipt, or deemed receipt, of the Exercise Notice or Major Transaction Early Termination Notice, or other event giving rise
to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination or
calculation within two (2) business days of such disputed determination or arithmetic calculation being submitted to the Holder,
then the Company shall, within two (2) business days submit via facsimile (i) the disputed determination of the closing price or
the Volume Weighted Average Price of the Company’s ADSs to an independent, reputable investment bank selected by the Company
and approved by the Holder, which approval shall not be unreasonably withheld or delayed, or (ii) the disputed arithmetic calculation
of the Exercise Price, Market Price or any Major Transaction Warrant Early Termination Price to the Company’s independent,
outside accountant or another accounting firm of United States national standing selected by the Company. The Company shall cause
the investment bank or the accountant, as the case may be, to perform the determinations or calculations and notify the Company
and the Holder of the results no later than five (5) business days from the time it receives the disputed determinations or calculations.
Such investment bank’s or accountant’s determination or calculation, as the case may be, shall be binding upon all
parties absent demonstrable error.

 

    8

     

    

 

(e)          Mandatory
Exercise. Subject to the provisions of this Section 3(e), at any time and from time to time, the Company may give written notice
(a “Mandatory Exercise Notice”) to the Holder of its intent to require a mandatory exercise of this Warrant. The Mandatory
Exercise Notice may only be given by the Company if (i) the closing price of the ADSs on NASDAQ, or if that is not the principal
trading market for the ADSs, such principal market on which the ADSs are traded or listed (the “Closing Market Price”),
for each of the 20 consecutive Trading Days immediately prior to the Mandatory Exercise Notice Date (as hereinafter defined) has
equaled or exceeded 400% of the Exercise Price, (ii) an effective registration statement is on file with the Securities and Exchange
Commission (“SEC”) covering the resale of the Warrant Shares issuable upon exercise of the Warrant, (iii) the Company
certifies in the Mandatory Exercise Notice that the Company (A) is not engaged in any negotiations, and (B) has not entered into
any agreement or arrangement, in each case, with respect to any transaction that would constitute a Major Transaction and (iv)
the Company certifies in the Mandatory Exercise Notice that an Event of Default (as defined in Section 11) has not occurred, and
that the issuance of Shares upon the exercise of this Warrant will not violate, or be prohibited by, any applicable laws, the requirements
of NASDAQ or any other trading market on which the ADSs are traded, or any other provisions of this Warrant. Following receipt
of a Mandatory Exercise Notice, the Holder shall be required to exercise the Warrant in full pursuant to the provisions of Section
3(a)(i) or 3(a)(ii) on or prior to the 30th Trading Day (the “Mandatory Exercise Date”) following the Mandatory Exercise
Notice Date; provided, however, that the Holder shall not be required to exercise the Warrant, and the Mandatory Exercise Notice
shall be of no further force and effect, if following delivery of the Mandatory Exercise Notice and prior to the Holder’s
exercise of this Warrant (i) the Closing Market Price on any two Trading Dates (including the Mandatory Exercise Notice Date) falls
below 400% of the Exercise Price, (ii) the Company is required to deliver to the Holder a Major Transaction Notice, (iii) the Warrant
Shares are no longer registered for resale pursuant to an effective registration statement or (iv) an Event of Default has occurred.
In order to be effective, a Mandatory Exercise Notice must be sent to the Holder by overnight mail, with an advance copy sent by
facsimile and e-mail (the date of facsimile and e-mail transmission is referred to as “Mandatory Exercise Notice Date”).

 

		4.	Transfer and Registration.

 

(a)          Transfer
Rights. Subject to the provisions of Section 8 of this Warrant, this Warrant may be transferred on the books of the Company,
in whole or in part, in person or by attorney, upon surrender of this Warrant properly completed and endorsed together with any
funds sufficient to pay any transfer tax in connection with such transfer. This Warrant shall be cancelled upon such surrender
and, as soon as practicable thereafter, the person to whom such transfer is made shall be entitled to receive a new Warrant or
Warrants as to the portion of this Warrant transferred, and Holder shall be entitled to receive a new Warrant as to the portion
hereof retained.

 

(b)          Registrable
Securities. The ADSs and Restricted ADSs issuable upon the Exercise of this Warrant have registration rights pursuant to the
Registration Rights Agreement.

 

		5.	Adjustments Upon Certain Events.

 

(a)          Participation.
The Holder, as the holder of this Warrant, shall be entitled to receive an amount payable in cash that is equivalent to all dividends
paid and distributions of any kind made to the holders of Ordinary Shares of the Company or ADSs to the same extent as if the Holder
had Exercised this Warrant into ADSs or Restricted ADSs (without regard to any limitations on exercise herein or elsewhere and
without regard to whether or not a sufficient number of shares are authorized and reserved to effect any such exercise and issuance)
and had held such ADSs or Restricted ADSs on the record date for such dividends and distributions. Payments under the preceding
sentence shall be made concurrently with the dividend or distribution to the holders of ADSs. The provisions of this Section 5(a)
shall not apply to stock dividends covered by the provisions of Section 5(b) below. This provision is included as one of the agreed
upon contractual terms of the Purchase Agreement.

 

(b)          Recapitalization
or Reclassification. If the Company shall at any time effect a stock split, payment of stock dividend, recapitalization, reclassification
or other similar transaction of such character that the Ordinary Shares shall be changed into or become exchangeable for a larger
or smaller number of shares, then upon the effective date thereof, the number of Ordinary Shares underlying the Warrant Shares
which Holder shall be entitled to purchase upon Exercise of this Warrant or receive value with respect to in a redemption shall
be increased or decreased, as the case may be, in direct proportion to the increase or decrease in the number of Ordinary Shares
by reason of such stock split, payment of stock dividend, recapitalization, reclassification or similar transaction, and the Exercise
Price shall be, in the case of an increase in the number of shares, proportionally decreased and, in the case of decrease in the
number of shares, proportionally increased. The Company shall give Holder the same notice it provides to holders of Ordinary Shares
of any transaction described in this Section 5(b).

 

    9

     

    

 

		(c)	Rights Upon Major Transaction.

 

(i)          Major
Transaction. In the event that a Major Transaction (as defined below) occurs, then (1) in the case of a Cash-Out Major Transaction
and in the case of a Mixed Major Transaction to the extent of the percentage of the cash consideration in the Mixed Major Transaction
(determined in accordance with the definition of a Mixed Major Transaction below), the Holder, at its option, may require the Company
to redeem the Holder’s outstanding Warrants in accordance with Section 5(c)(iii) below and (2) in the case of all other Major
Transactions and in the case of a Mixed Major Transaction to the extent of the percentage of the consideration represented by securities
of a Successor Entity in the Mixed Major Transaction, the Holder shall have the right to exercise this Warrant as a Cashless Major
Exercise in accordance with Section 3(b). The Holder may waive its rights under this Section 5(c) with respect to such Major Transaction.
Consummation of each of the following events shall constitute a “Major Transaction”:

 

(A)         a
consolidation, merger, exchange of shares, recapitalization, reorganization, business combination or other similar event, following
which the holders of Ordinary Shares (including holders of ADSs attributable to underlying Ordinary Shares) immediately preceding
such consolidation, merger, exchange, recapitalization, reorganization, combination or event either (a) no longer hold a majority
of the Ordinary Shares (including ADSs attributable to such Ordinary Shares) or the shares of the Successor Entity (or the Parent
Entity of a Successor Entity) or (b) no longer have the ability to elect a majority of the board of directors of the Company or
the Successor Entity (collectively, a “Change of Control Transaction”);

 

(B)          a
sale or transfer of all or substantially all of the Company’s assets;

 

(C)          a
purchase, tender or exchange offer, made to the holders of outstanding Ordinary Shares or ADSs, such that following the consummation
of such purchase, tender or exchange offer a Change of Control Transaction shall have occurred; or

 

		(D)	[Intentionally Omitted]

 

(E)          the
liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) affecting the Company.

 

		(F)	[Intentionally Omitted]

 

		(G)	[Intentionally Omitted]

 

		(ii)	[Intentionally Omitted]

 

    10

     

    

 

(iii)         Notice;
Major Transaction Early Termination Right; Notice of Cashless Major Exercise. At least twenty (20) days prior to the consummation
of any Major Transaction, but, in any event, within five (5) business days following the first to occur of (x) the date of the
public announcement of such Major Transaction if such announcement is made before 4:00 p.m., New York City time, or (y) the day
following the public announcement of such Major Transaction if such announcement is made on and after 4:00 p.m., New York City
time, the Company shall deliver written notice thereof via facsimile and overnight courier to the Holder (a “Major Transaction
Notice”). Other than in respect of all or a portion of the Warrant that is eligible for a Cashless Major Exercise (without
taking into consideration the 9.985% Cap or the Beneficial Ownership Cap), the Holder may, by delivery of written notice (“Major
Transaction Early Termination Notice”) to the Company and the Transfer Agent at any time during the period beginning after
the Holder’s receipt of a Major Transaction Notice and ending five (5) Trading Days prior to the consummation of such Major
Transaction (the “Early Termination Period”), require the Company to redeem (an “Early Termination Upon Major
Transaction”), effective immediately prior to the consummation of such Major Transaction, all or any portion of this Warrant
not eligible to be exercised as a Cashless Major Exercise (without taking into consideration the 9.985% Cap or the Beneficial Ownership
Cap). The Major Transaction Early Termination Notice shall indicate the portion of the Warrant that the Holder is electing to have
redeemed in accordance with the terms hereof. Such portion of this Warrant (the “Redeemable Portion”) shall be redeemed
by the Company at a price (the “Major Transaction Warrant Early Termination Price”) payable in cash equal to the “Black
Scholes Value” of the Redeemable Portion determined by use of the Black Scholes Option Pricing Model using the criteria set
forth in Schedule 1 hereto (the “Black Scholes Value”); provided, however, that in the event of a Major Transaction
specified in Section 5(c)(i)(A), (B) or (C) that is with the Holder, the original Holder or any of their respective Affiliates,
the Major Transaction Warrant Early Termination Price shall equal the Intrinsic Value of the Redeemable Portion.

 

For purposes herein, “Intrinsic Value”
shall be determined using the formula Y(SP–EP) where Y is as defined in Section 3(a)(ii) above, SP equals the Stock Price
(as defined below) and EP equals the prevailing Exercise Price at the time of calculation.

 

“Stock Price” shall mean the greater
of (1) the closing price of the ADSs on NASDAQ, or, if that is not the principal trading market for the ADSs, such principal market
on which the ADSs are traded or listed (the “Closing Market Price”) on the trading day immediately preceding the date
on which a Major Transaction is consummated, or (2) the first Closing Market Price following the date of the definitive agreement
with respect to a Major Transaction.

 

To the extent the Holder shall elect to effect a Cashless Major
Exercise in respect of a Major Transaction, the Holder shall deliver its exercise notice in accordance with Section 3(b), within
the Early Termination Period. In the event of a Major Transaction, Holders of Restricted ADSs shall be deemed to be holders of
ADSs with respect to such Major Transaction.

 

(iv)         Escrow;
Payment of Major Transaction Warrant Early Termination Price. Following the receipt of a Major Transaction Early Termination
Notice or a notice of a Cashless Major Exercise from the Holder, the Company shall not effect a Major Transaction that is being
treated as an Early Termination Upon Major Transaction or in connection with which this Warrant is eligible to be exercised as
a Cashless Major Exercise unless it either (a) obtains the written agreement of the Successor Entity that payment of the Major
Transaction Warrant Early Termination Price and/or issuance of the applicable Cashless Major Shares shall be made to the Holder
prior to consummation of such Major Transaction and such issuance or payment shall be a condition precedent to consummation of
such Major Transaction or (b) it shall first place into an escrow account with an independent escrow agent, at least three (3)
business days prior to the closing date of such Major Transaction (the “Major Transaction Escrow Deadline”), an amount
in ADSs or cash, as applicable, equal to the Major Transaction Warrant Early Termination Price and/or applicable Exercise Shares.
If an escrow account is required to be established pursuant to the preceding sentence, concurrently upon closing of such Major
Transaction, the Company shall pay or shall instruct the escrow agent to pay the Major Transaction Warrant Early Termination Price
and/or to deliver the applicable Cashless Major Shares to the Holder. For purposes of determining the amount, if any, required
to be placed in escrow pursuant to the provisions of this subsection (iv) and without affecting the amount of the actual Major
Transaction Warrant Early Termination Price and/or the number of applicable Cashless Major Shares, the calculation of the “Stock
Price” referred to in Schedule 1 hereto shall be determined based on the Closing Market Price (as defined on Schedule I)
of the ADSs on the Trading Day immediately preceding the date that the funds and/or applicable Exercise Shares, as applicable,
are deposited with the escrow agent.

 

(v)         Injunction.
Following the receipt of a Major Transaction Early Termination Notice or notice of a Cashless Major Exercise from the Holder, in
the event that the Company attempts to consummate a Major Transaction without either (1) placing the Major Transaction Warrant
Early Termination Price, or applicable Exercise Shares, as applicable, in escrow in accordance with subsection (iv) above, (2)
payment of the Major Transaction Warrant Early Termination Price or issuance of the applicable Exercise Shares, as applicable,
to the Holder prior to consummation of such Major Transaction or (3) obtaining the written agreement of the Successor Entity described
in subsection (iv) above, the Holder shall have the right to apply for an injunction in any state or federal courts sitting in
the City of New York, borough of Manhattan to prevent the closing of such Major Transaction until the Major Transaction Warrant
Early Termination Price is paid to the Holder, in full or the applicable Exercise Shares are delivered, as applicable.

 

    11

     

    

  

An early termination required by this Section 5(c) shall be
made in accordance with the provisions of Section 12 and shall have priority to payments to holders of Ordinary Shares and ADSs
in connection with a Major Transaction. To the extent an early termination required by this Section 5(c)(iii) is deemed or determined
by a court of competent jurisdiction in the United States to be prepayments of the Warrant by the Company, such early termination
shall be deemed to be voluntary prepayments. Notwithstanding anything to the contrary in this Section 5, until the Major Transaction
Warrant Early Termination Price is paid in full, this Warrant may be exercised, in whole or in part, by the Holder into ADSs or
Restricted ADSs, as applicable, or in the event the Exercise Date is after the consummation of the Major Transaction, shares of
publicly traded common stock or American Depositary Shares (or their equivalent) of the Successor Entity pursuant to Section 5(c).
The parties hereto agree that in the event of the Company’s early termination of any portion of the Warrant under this Section
5(c), the Holder’s damages would be uncertain and difficult to estimate because of the parties’ inability to predict
future interest rates and the uncertainty of the availability of a suitable substitute investment opportunity for the Holder. Accordingly,
any premium due under this Section 5(c) is intended by the parties to be, and shall be deemed, a reasonable estimate of the Holder’s
actual loss of its investment opportunity and not as a penalty.

 

For purposes hereof:

 

“Another Entity” shall mean an entity in which the
holders of a majority of the Ordinary Shares of the Company immediately prior to the consummation of a Major Transaction do not
hold a majority of the equity securities in such entity.

 

“Cash-Out Major Transaction” means a Major Transaction
in which the consideration payable to holders of Ordinary Shares in connection with the Major Transaction consists solely of cash.

 

“Cashless Default Exercise” shall mean an exercise
of this Warrant as a “Cashless Default Exercise” in accordance with Section 3(c) and 11(b) hereof.

 

“Cashless Major Exercise” shall mean an exercise
of this Warrant or portion thereof as a “Cashless Major Exercise” in accordance with Section 3(b) and 5(c)(i) hereof.

 

“Cashless Major Shares” means ADSs or Restricted
ADSs issued or issuable pursuant to a Cashless Major Exercise.

 

“Eligible Market” means the over the counter Bulletin
Board, the New York Stock Exchange, Inc., the NYSE Arca, the NASDAQ Capital Market, the NASDAQ Global Market, the NASDAQ Global
Select Market or the NYSE MKT (or, in each case, any successor thereto).

 

“Mixed Major Transaction” means a Major Transaction
in which the consideration payable to the shareholders of the Company consists partially of cash and partially of securities of
a Successor Entity. If the Successor Entity is a Publicly Traded Successor Entity, the percentage of consideration represented
by securities of such Successor Entity shall be equal to the percentage that the value of the aggregate anticipated number of shares
of the Publicly Traded Successor Entity to be issued to holders of Ordinary Shares of the Company represents in comparison to the
aggregate value of all consideration, including cash consideration, in such Mixed Major Transaction, as such values are set forth
in any definitive agreement for the Mixed Major Transaction that has been executed at the time of the first public announcement
of the Major Transaction or, if no such value is determinable from such definitive agreement, based on the average of the closing
market prices for shares of the Publicly Traded Successor Entity on its principal securities exchange for the five (5) Trading
Day period commencing on the second Trading Day preceding the first public announcement of the Mixed Major Transaction. If the
Successor Entity is a Private Successor Entity, the percentage of consideration represented by securities of such Successor Entity
shall be determined in good-faith by the Company’s Board of Directors

 

    12

     

    

  

“Parent Entity” of a Person means an entity that,
directly or indirectly, controls the applicable Person and whose common stock or equivalent equity security is quoted or listed
on an Eligible Market, or, if there is more than one such Person or Parent Entity, the Person or Parent Entity with the largest
public market capitalization as of the date of consummation of a Major Transaction.

 

“Person” means an individual, a limited liability
company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government
or any department or agency thereof.

 

“Private Successor Entity” means a Successor Entity
that is not a Publicly Traded Successor Entity.

 

“Publicly Traded Successor Entity” means a Successor
Entity that is a publicly traded corporation whose common stock is quoted on or listed for trading on an Eligible Market (as defined
above).

 

“Successor Entity” means any Person purchasing the
Company’s assets or Ordinary Shares, or any successor entity resulting from such Major Transaction, or if the Warrant is
to be exercisable for shares of capital stock of its Parent Entity (as defined above), its Parent Entity.

 

(d)          Exercise
Price Adjusted. As used in this Warrant, the term “Exercise Price” shall mean the purchase price per share specified
in Section 3(a) of this Warrant, until the occurrence of an event stated in this Section 5 or otherwise set forth in this Warrant,
and thereafter shall mean said price as adjusted from time to time in accordance with the provisions of said subsection.

 

(e)          Adjustments:
Additional Shares, Securities or Assets. In the event that at any time, as a result of an adjustment made pursuant to this
Section 5 or otherwise, Holder shall, upon Exercise of this Warrant, become entitled to receive shares and/or other securities
or assets (other than ADSs or Restricted ADSs) then, wherever appropriate, all references herein to ADSs or Restricted ADSs shall
be deemed to refer to and include such shares and/or other securities or assets; and thereafter the number of such shares and/or
other securities or assets shall be subject to adjustment from time to time in a manner and upon terms as nearly equivalent as
practicable to the provisions of this Section 5.

 

(f)          Notice
of Adjustments. Whenever the Exercise Price is adjusted pursuant to the terms of this Warrant, the Company shall promptly mail
to the Holder a notice (an “Exercise Price Adjustment Notice”) setting forth the Exercise Price after such adjustment
and setting forth a statement of the facts requiring such adjustment. The Company shall, upon the written request at any time of
the Holder, furnish to such Holder a like Warrant setting forth (i) such adjustment or readjustment, (ii) the Exercise Price at
the time in effect and (iii) the number of ADSs or Restricted ADSs and the amount, if any, of other securities or property which
at the time would be received upon Exercise of the Warrant. For purposes of clarification, whether or not the Company provides
an Exercise Price Adjustment Notice pursuant to this Section 5(f), upon the occurrence of any event that leads to an adjustment
of the Exercise Price, the Holder would be entitled to receive a number of Exercise Shares based upon the new Exercise Price, as
adjusted, for exercises occurring on or after the date of such adjustment, regardless of whether the Holder accurately refers to
the adjusted Exercise Price in the Exercise Form.

 

		6.	Fractional Interests.

 

No fractional shares or scrip representing fractional shares
shall be issuable upon the Exercise of this Warrant, but on Exercise of this Warrant, Holder may purchase only a whole number of
ADSs or Restricted ADSs. If, on Exercise of this Warrant, Holder would be entitled to a fractional ADS or Restricted ADS or a right
to acquire a fractional ADS or Restricted ADS, such fractional share shall be disregarded and the number of ADSs or Restricted
ADSs issuable upon Exercise shall be the next higher whole number of shares.

 

    13

     

    

  

		7.	Reservation of Shares.

 

The Company covenants and agrees that upon the Exercise of this
Warrant in accordance with the terms hereof, all ADSs and Restricted ADSs issuable upon such Exercise and all underlying Ordinary
Shares shall be duly and validly issued, fully paid and nonassessable and not subject to preemptive rights, rights of first refusal
or similar rights of any Person (the “Issuance Conditions”). The Company will take all such reasonable action as may
be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of NASDAQ, or such other principal trading market upon which ADSs may be listed if no longer on NASDAQ.
For so long as the Warrant is outstanding and the Company’s Board of Directors has not taken an action consistent with Section
2(c)(ii), the Company shall use commercially reasonable best efforts to maintain the Deposit Agreement, and shall not terminate
the Deposit Agreement nor allow it to lapse due to the Company’s failure to appoint a successor Depositary upon the resignation
of the Deposit in accordance with the provisions of the Deposit Agreement. Upon the termination of Bank of New York as Depositary
or Restricted ADR Depositary, the Company shall promptly appoint a successor Depositary or Restricted ADR Depositary, as the case
may be, and all references herein to Depositary or Restricted ADR Depositary, as the case may be, shall thereafter refer to such
successor Depositary or Restricted ADR Depositary, as the case may be. Without the consent of the Holder, the Company shall not
amend the Deposit Agreement in a manner that adversely affects the rights of the Holder in a materially disproportionate manner
to the rights of other ADS holders.

 

		8.	Restrictions on Transfer.

 

(a)          Registration
or Exemption Required. This Warrant has been issued in a transaction exempt from the registration requirements of the Securities
Act by virtue of Regulation D and exempt from state registration or qualification under applicable state laws. None of the Warrant,
the Exercise Shares or Failure Payment Shares may be pledged, transferred, sold or assigned except pursuant to an effective registration
statement or an exemption to the registration requirements of the Securities Act and applicable state laws including, without limitation,
a so-called “4[(a)](1) and a half” transaction.

 

(b)          Assignment.
Subject to Section 8(a) and the requirement of compliance with applicable law, the Holder may sell, transfer, assign, pledge, or
otherwise dispose of this Warrant, in whole or in part. Holder shall deliver a written notice to Company, substantially in the
form of the Assignment attached hereto as Exhibit B, indicating the Person or Persons to whom the Warrant shall be assigned
and the respective number of warrants to be assigned to each assignee. The Company shall effect the assignment within three (3)
business days (the “Transfer Delivery Period”), and shall deliver to the assignee(s) designated by Holder a Warrant
or Warrants of like tenor and terms for the appropriate number of shares. This Warrant and the rights evidenced hereby shall inure
to the benefit of and be binding upon the successors and assigns of the Holder. The provisions of this Warrant are intended to
be for the benefit of all Holders from time to time of this Warrant, and shall be enforceable by any such Holder. For avoidance
of doubt, in the event Holder notifies the Company that such sale or transfer is a so called “4[(a)](1) and half” transaction,
the parties hereto agree that a legal opinion from outside counsel for the Holder delivered to counsel for the Company substantially
in the form attached hereto as Exhibit C shall be required and shall be the only requirement to satisfy an exemption from
registration under the Securities Act to effectuate such “4[(a)](1) and half” transaction.

 

		9.	Noncircumvention.

 

The Company hereby covenants and agrees that the Company will
not, by amendment of its constitution, bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme
of arrangement, dissolution, issue or sale of securities, or any other voluntary action, take any action for the purpose of avoiding
or seeking to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry
out all the provisions of this Warrant. Without limiting the generality of the foregoing, the Company (i) shall not increase the
nominal value of any Ordinary Shares underlying ADSs or Restricted ADSs receivable upon the exercise of this Warrant, and (ii)
shall take all such actions as may be reasonably necessary or appropriate in order that the Company may validly and legally issue
fully paid and nonassessable Ordinary Shares in respect of ADSs and Restricted ADSs issued upon the exercise of this Warrant.

 

    14

     

    

  

		10.	Events of Failure; Definition of Black Scholes Value.

 

		(a)	Definition.

 

The occurrence of each of the following shall be considered
to be an “Event of Failure.”

 

(i)          A
Delivery Failure occurs, where a “Delivery Failure” shall be deemed to have occurred if the Company fails to deliver
Ordinary Shares satisfying the Issuance Conditions to the Depositary or fails to cause the Exercise Shares satisfying the Issuance
Conditions to be delivered to the Holder within any applicable Delivery Period;

 

(ii)         a
Transfer Delivery Failure occurs, where a “Transfer Delivery Failure” shall be deemed to have occurred if the Company
fails to use its commercially reasonable best efforts to deliver a Warrant within any applicable Transfer Delivery Period; and

 

(iii)        a
Registration Failure (as defined below).

 

For purpose hereof, “Registration Failure” means
that (A) the Company fails to file with the SEC on or before the Filing Deadline (as defined in the Registration Rights Agreement)
any Registration Statement required to be filed pursuant to the terms and conditions of the Registration Rights Agreement, (B)
the Company fails to use its commercially reasonable efforts to obtain effectiveness with the SEC, prior to the Registration Deadline
(as defined in the Registration Rights Agreement), and if such Registration Statement is not so filed prior to the Registration
Deadline, as soon as possible thereafter, of any Registration Statement (as defined in the Registration Rights Agreement) that
are required to be filed pursuant to the terms and conditions of the Registration Rights Agreement, or fails to use commercially
reasonable efforts to keep such Registration Statement current and effective as required in the Registration Rights Agreement,
(C) the Company fails to file any additional Registration Statements required to be filed pursuant to the terms and conditions
of the Registration Rights Agreement on or before the Additional Filing Deadline (as defined in the Registration Rights Agreement)
or fails to use its commercially reasonable efforts to cause such new Registration Statement to become effective on or before the
Additional Registration Deadline, and if such effectiveness does not occur within such period, as soon as possible thereafter,
(D) the Company fails to file any amendment to any Registration Statement, or any additional Registration Statement required to
be filed pursuant to the terms and conditions of the Registration Rights Agreement within twenty (20) days of the applicable Registration
Trigger Date (as defined in the Registration Rights Agreement), or fails to use its commercially reasonable efforts to cause such
amendment and/or new Registration Statement to become effective within sixty (60) days of the applicable Registration Trigger Date,
and, if such effectiveness does not occur within such period, as soon as possible thereafter, (E) any Registration Statement required
to be filed under the Registration Rights Agreement, after its initial effectiveness and during the Registration Period (as defined
in the Registration Rights Agreement), lapses in effect or sales of all of the Registrable Securities (as defined in the Registration
Rights Agreement) cannot otherwise be made thereunder (whether by reason of the Company’s failure to amend or supplement
the prospectus included therein in accordance with the Registration Rights Agreement, or the Company’s failure to file and,
use commercially reasonable efforts to obtain effectiveness with the SEC of an additional Registration Statement or amended Registration
Statement required, in each case, pursuant to terms and conditions of the Registration Rights Agreement), or (F) the Company fails
to provide a written response to any comments to any Registration Statement submitted by the SEC within twenty (20) days of the
date that such SEC comments are received by the Company. For the avoidance of doubt, with respect to any event set forth in the
definition of Registration Failure, in no event shall a Registration Failure occur in respect of the Company’s failure to
cause such event to occur where the Company has used the requisite standards, if any, to cause such event to occur, in accordance
with the definition of Registration Failure.

 

    15

     

    

 

(b)          Failure
Payments; Black-Scholes Determination. The Company understands that any Event of Failure (as defined above) could result in
economic loss to the Holder. In the event that any Event of Failure occurs, as compensation to the Holder for such loss, the Company
agrees to pay (as liquidated damages and not as a penalty) to the Holder an amount (“Failure Payments”), payable, at
the Company’s option, either (i) in cash or (ii) in ADSs or Restricted ADSs, as applicable ( the “Failure Payment Shares”),
that are valued for these purposes at the Volume Weighted Average Price on the date of such calculation, in each case equal to
18% per annum (or the maximum rate permitted by applicable law, whichever is less) of the Black-Scholes value (as determined below)
of the remaining unexercised portion of this Warrant on the date of such Event of Failure (as recalculated on the first business
day of each month thereafter for as long as Failure Payments shall continue to accrue), which shall accrue daily from the date
of such Event of Failure until the Event of Failure is cured, accruing daily and compounded monthly; provided, however, that during
any period that the Company does not qualify as a “foreign private issuer” as defined under Rule 3b-4 promulgated under
the Exchange Act, the Holder shall only receive up to such amount of ADSs or Restricted ADSs in respect of Failure Payments such
that the Holder and any other persons or entities whose beneficial ownership (including through the ownership of ADSs) would be
aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act (including shares held by any “group”
of which the Holder is a member, but excluding shares beneficially owned by virtue of the ownership of securities or rights to
acquire securities that have limitations on the right to convert, exercise or purchase similar to the limitation set forth herein)
shall not collectively beneficially own greater than 9.985% of the total number of Ordinary Shares (including through ownership
of ADSs) then issued and outstanding. For purposes of clarification, it is agreed and understood that Failure Payments shall continue
to accrue following any Event of Default until the applicable Default Amount is paid in full.

 

In the event that the Company (i) has, by the Filing Deadline
(as defined the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement)
covering the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments
to the Registration Statement that the Company has received from the SEC, within seven (7) Business Days of such receipt, and nevertheless
the SEC has not declared effective a Registration Statement covering the full number of Warrant Shares issuable upon exercise of
the Warrants by the Registration Deadline (as defined in the Registration Rights Agreement) then, the Failure Payments attributable
to such late Registration Effectiveness shall be reduced from 18% to 15% (calculated as set forth above). For the avoidance of
doubt, nothing in the immediately preceding sentence shall be construed to increase the obligations of the Company under the definition
of “Registration Failure” above. The Company shall satisfy any Failure Payments under this Section pursuant to Section
10(c) below. Failure Payments are in addition to any shares that the Holder is entitled to receive upon Exercise of this Warrant.

 

For purposes hereof, the “Black-Scholes” value of
a Warrant shall be determined by use of the Black Scholes Option Pricing Model using the criteria set forth on Schedule 1 hereto.

 

(c)          Payment
of Accrued Failure Payments. The Failure Payments for each Event of Failure shall be delivered (and, if applicable, issued)
on or before the fifth (5th) business day of each month following a month in which Failure Payments accrued. Nothing herein shall
limit the Holder’s right to pursue actual damages (to the extent in excess of the Failure Payments) for the Company’s
Event of Failure, and the Holder shall have the right to pursue all remedies available at law or in equity (including a decree
of specific performance and/or injunctive relief). Notwithstanding the above, if a particular Event of Failure results in an Event
of Default pursuant to Section 11 hereof, then the Failure Payment, for that Event of Failure only, shall be considered to have
been satisfied upon payment to the Holder of an amount equal to the greater of (i) the Failure Payment, or (ii) the Default Amount,
payable in accordance with Section 11.

 

(d)          Maximum
Interest Rate. Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be
deemed to establish or require the payment of a rate of interest or other charges in excess of the maximum permitted by applicable
law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum permitted
by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company to the Holder and thus
refunded to the Company.

 

    16

     

    

 

		11.	Default.

 

 

(a)          Events
Of Default. Each of the following events shall be considered to be an “Event of Default,” unless waived by the
Holder:

 

(i)           Failure
To Effect Registration. With respect to all Registration Failures, a Registration Failure occurs and remains uncured for a
period of more than thirty (30) days (or forty-five (45) days in the case where the Company has, by the Filing Deadline (as defined
the Registration Rights Agreement) filed a Registration Statement (as defined in the Registration Rights Agreement) covering this
Warrant and the number of shares required by the Registration Rights Agreement, and (ii) has responded in writing to any comments
to the Registration Statement that the Company has received from the SEC, within twenty (20) days of such receipt, and nevertheless
the SEC has not declared effective a Registration Statement covering this Warrant and the Shares by the Registration Deadline (as
defined in the Registration Rights Agreement)), and such Registration Failure relates solely to the Company’s failure
to have the Registration Statement declared effective by the Registration Deadline (as defined in the Registration Rights Agreement),
and with respect to a Registration Failure provided in clause (E) of the definition of “Registration Failure”, such
Registration Failure occurs and remains uncured for a period of more than thirty (30) days. For the avoidance of doubt, nothing
in the immediately preceding sentence shall be construed to increase the obligations of the Company under the definition of “Registration
Failure” above.

 

(ii)           Continuing
Delivery Failure. A Delivery Failure (as defined above) occurs and remains uncured for a period of more than twenty (20) days;
or at any time, the Company announces or states in writing that it will not honor its obligations to cause the issuance of Ordinary
Shares to the Depositary or the Restricted ADR Depositary, as applicable and ADSs or Restricted ADS, as applicable, to the Holder
upon Exercise by the Holder of the Exercise rights of the Holder or, if applicable, to deliver cash, in accordance with the terms
of this Warrant.

 

(iii)          Legend
Removal Failure. A Legend Removal Failure (as defined below) occurs and remains uncured for a period of twenty (20) days; and

 

(iv)          Corporate
Existence; Major Transaction. The Company has failed to either (1) place the Major Transaction Warrant Early Termination Price
or the Exercise Shares issuable upon exercise of a Cashless Major Exercise, as the case may be, into escrow or (2) obtain the written
agreement of the Successor Entity as described in Section 5(c)(iv) or the Company has failed to instruct the escrow agent to release
such amount or such shares, as the case may be, to the Holder pursuant to Section 5(c)(iv).

 

A “Legend Removal Failure” shall be deemed to have
occurred if the Company fails to use its commercially reasonable best efforts to issue this Warrant and/or Exercise Shares without
a restrictive legend, or fails to use its commercially reasonable best efforts to cause the Depositary to remove a restrictive
legend, when and as required under Section 2(e) hereof;

 

		(b)	Mandatory Early Termination.

 

(i)            Mandatory
Early Termination Amount; Cashless Default Exercise. If any Events of Default shall occur then, unless waived by the Holder,
upon the occurrence and during the continuation of any Event of Default, at the option of the Holder, such option exercisable through
the delivery of written notice to the Company by such Holder (the “Default Notice”), the Company shall have the right
to terminate the outstanding amount of this Warrant and pay to the Holder (a “Mandatory Early Termination”), in full
satisfaction of its obligations hereunder by delivery of a notice to such effect to the Holder within two (2) Business Days following
receipt of the Default Notice, an amount payable in cash (the “Mandatory Early Termination Amount” or the “Default
Amount”) equal to the greater of (i) the Black-Scholes value (as determined in accordance with Section 10(b)) of the remaining
unexercised portion of this Warrant on the date of such Default Notice and (2) the Black-Scholes value (also as determined in accordance
with Section 10(b)) of the remaining unexercised portion of this Warrant on the Trading Day immediately preceding the date that
the Mandatory Early Termination Amount is paid to the Holder. In the event the Company does not exercise its right to consummate
a Mandatory Early Termination, then the Holder shall have the right to exercise this Warrant pursuant to a Cashless Default Exercise
in accordance with Section 3(c) above.

 

    17

     

    

  

The Mandatory Early Termination Amount shall be payable within
five (5) Business Days following the date of the applicable Default Notice.

 

(ii)          Liquidated
Damages. The parties hereto acknowledge and agree that the sums payable as Failure Payments or pursuant to a Mandatory Early
Termination shall give rise to liquidated damages and not penalties. The parties further acknowledge that (i) the amount of loss
or damages likely to be incurred by the Holder is incapable or is difficult to precisely estimate, (ii) the amounts specified bear
a reasonable proportion and are not plainly or grossly disproportionate to the probable loss likely to be incurred by the Holder,
and (iii) the parties are sophisticated business parties and have been represented by sophisticated and able legal and financial
counsel and negotiated this Agreement at arm’s length.

 

The Default Amount, together with all other amounts payable
hereunder, shall immediately become due and payable, all without demand, presentment or notice, all of which hereby are expressly
waived, together with all costs, including, without limitation, legal fees and expenses, of collection, and the Holder shall be
entitled to exercise all other rights and remedies available at law or in equity.

 

		(c)	[Intentionally Omitted]

 

(d)          Injunction.
In the event that an Event of Default pertains to a Legend Removal Failure, the Company may not refuse such unlegended share delivery
based on any claim that such Holder or any one associated or affiliated with such Holder has been engaged in any violation of law,
unless, within sixty (60) days of the applicable Default Notice an injunction from a United States court, on prior notice to Holder,
restraining and or enjoining Exercise of all or part of said Warrant shall have been sought and obtained by the Company.

 

(e)          Remedies,
Other Obligations, Breaches And Injunctive Relief. The remedies provided in this Warrant shall be cumulative and in addition
to all other remedies available under this Warrant, the Purchase Agreement and the Registration Rights Agreement, at law or in
equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of
the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges
that a breach by it of its obligations hereunder will cause irreparable harm to the Holder and that the remedy at law for any such
breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of
this Warrant shall be entitled, in addition to all other available remedies, to seek an injunction restraining any breach, without
the necessity of showing economic loss and without any bond or other security being required.

 

		12.	Holder’s Early Terminations.

 

Mechanics of Holder’s Early Terminations. In the
event that the Company does not deliver the applicable Major Transaction Warrant Early Termination Price or Default Amount or the
Exercise Shares in respect of a Cashless Major Exercise or a Cashless Default Exercise, as the case may be, to the Holder within
the time period or as otherwise required pursuant to the terms hereof, at any time thereafter the Holder shall have the option,
upon notice to the Company, in lieu of redemption, early termination, Cashless Major Exercise or Cashless Default Exercise, as
the case may be, to require the Company to promptly return to the Holder all or any portion of this Warrant that was submitted
for redemption, early termination or exercise. Upon the Company’s receipt of such notice, (x) the redemption, applicable
early termination or exercise, as the case may be, shall be null and void with respect to such applicable portion of this Warrant,
(y) the Company shall immediately return this Warrant, or issue a new Warrant to the Holder representing the portion of this Warrant
that was submitted for redemption, early termination or exercise and (z) the Exercise Price of this Warrant or such new Warrant
shall be adjusted to the lesser of (A) the Exercise Price as in effect on the date on which the applicable redemption, early termination,
default or exercise notice, as the case may be, is voided and (B) the lowest closing price for the ADSs on NASDAQ, or, if NASDAQ
is not the principal trading market for the ADSs, the principal securities exchange or other securities market on which the ADSs
are then being traded, during the period beginning on and including the date on which the applicable redemption, early termination,
default or exercise notice, as the case may be, is delivered to the Company and ending on and including the date on which the applicable
redemption, early termination or exercise is voided. The Holder’s delivery of a notice voiding a redemption, early termination
or exercise and exercise of its rights following such notice shall not affect the Company’s obligations to make any payments
of Failure Payments which have accrued prior to the date of such notice with respect to the Warrant subject to such notice.

 

    18

     

    

  

		13.	Benefits of this Warrant.

 

Nothing in this Warrant shall be construed to confer upon any
person other than the Company and Holder any legal or equitable right, remedy or claim under this Warrant and this Warrant shall
be for the sole and exclusive benefit of the Company and Holder.

 

		14.	Governing Law.

 

All questions concerning the construction, validity, enforcement
and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the
State of New York, without regard to the principles of conflicts of law thereof (and without prejudice to the applicability of
Irish law to the issuance of Ordinary Shares underlying the ADSs or Restricted ADSs). Each party agrees that all legal proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Agreement (whether brought against
a party hereto or its respective affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively
in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction
of the state and federal courts sitting in the City of New York, borough of Manhattan for the adjudication of any dispute hereunder
or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees
not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy
thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. The parties hereby waive all rights to a trial by jury. If either party shall commence an action or proceeding to enforce
any provisions of this Agreement, then the prevailing party in such action or proceeding shall be reimbursed by the other party
for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.

 

		15.	Loss of Warrant.

 

Upon receipt by the Company of evidence of the loss, theft,
destruction or mutilation of this Warrant, and (in the case of loss, theft or destruction) of indemnity or security reasonably
satisfactory to the Company, and upon surrender and cancellation of this Warrant, if mutilated, the Company shall execute and deliver
a new Warrant of like tenor and date.

 

		16.	Notice or Demands.

 

Notices or demands pursuant to this Warrant to be given or made
by Holder to or on the Company shall be sufficiently given or made if sent by certified or registered mail, return receipt requested,
postage prepaid or via express delivery with a nationally recognized courier, and addressed, until another address is designated
in writing by the Company, to the address set forth in Section 2(a) above. Notices or demands pursuant to this Warrant to be given
or made by the Company to or on Holder shall be sufficiently given or made if sent by certified or registered mail, return receipt
requested, postage prepaid or via express delivery with a nationally recognized courier, and addressed, to the address of Holder
set forth in the Company’s records, until another address is designated in writing by Holder.

 

    19

     

    

  

		17.	[Intentionally Omitted]

 

18.         Currency.
All amounts owing under the Warrant that, in accordance with its terms, are paid in cash shall be paid in United States dollars.
“Exchange Rate” means, in relation to any amount of currency to be converted from United States dollars pursuant to
Section 20 of the Warrant, the United States dollar exchange rate as published in the Wall Street Journal on the relevant date
of calculation (it being understood and agreed that where an amount is calculated with reference to, or over, a period of time,
the date of calculation shall be the final date of such period of time).

 

19.         Taxes.
The purchase of ADSs or Restricted ADSs upon the exercise in whole or in part of the Warrant will not be subject to withholding
tax in Ireland.

 

		20.	Judgment Currency.

 

(a)          If,
for the purpose of obtaining or enforcing judgment against the Company in any court in any jurisdiction, it becomes necessary to
convert into any other currency (such other currency being hereinafter in this Section 20(a) referred to as the “Judgment
Currency”) an amount due in United States dollars under the Warrant, the exercise shall be made at the Exchange Rate prevailing
on the business day immediately preceding:

 

(i)          the
date actual payment of the amount due, in the case of any proceeding in the courts of New York or in the courts of any other jurisdiction
that will give effect to such exercise being made on such date; or

 

(ii)         the
date on which the Irish or any other non-U.S. court determines, in the case of any proceeding in the courts of any other jurisdiction
(the date as of which such exercise is made pursuant to this Section 20(a)(ii) being hereinafter referred to as the “Judgment
Exercise Date”).

 

(b)          If
in the case of any proceeding in the court of any jurisdiction referred to in Section 20(a)(ii) above, there is a change in the
Exchange Rate prevailing between the Judgment Exercise Date and the date of actual payment of the amount due, the applicable party
shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted at the
Exchange Rate prevailing on the date of payment, will produce the amount of United States dollars which could have been purchased
with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on the Judgment
Exercise Date.

 

(c)          Any
amount due from the Company under this provision shall be due as a separate debt and shall not be affected by judgment being obtained
for any other amounts due under or in respect of the Warrant.

 

		21.	No Third-Party Beneficiaries.

 

This Warrant is for the sole benefit of the Company and the
Holder and their respective successors and, in the case of the Holder, permitted assigns and nothing herein, express or implied,
is intended to or shall confer upon any other Person any legal or equitable right, benefit or remedy of any nature whatsoever,
under or by reason of this Warrant.

 

		22.	Headings.

 

The headings in this Warrant are for reference only and shall
not affect the interpretation of this Warrant.

 

    20

     

    

 

		23.	Amendment and Modification; Waiver.

  

Except as otherwise provided herein, this Warrant may only be
amended, modified or supplemented by an agreement in writing signed by the Company and the Holder. No waiver by the Company or
the Holder of any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so
waiving. No waiver by any party shall operate or be construed as a waiver in respect of any failure, breach or default not expressly
identified by such written waiver, whether of a similar or different character, and whether occurring before or after that waiver.
No failure to exercise, or delay in exercising, any rights, remedy, power or privilege arising from this Warrant shall operate
or be construed as a waiver thereof; nor shall any single or partial exercise of any right, remedy, power or privilege hereunder
preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

 

		24.	Severability.

 

If any term or provision of this Warrant is invalid, illegal
or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision
of this Warrant or invalidate or render unenforceable such term or provision in any other jurisdiction.

 

[The remainder of this page is intentionally
blank.]

 

    21

     

    

  

IN WITNESS WHEREOF, this Warrant has been executed and delivered
as a Deed as of the 1st day of January, 2017.

 

	 	AVADEL PHARMACEUTICALS PLC
	 	 	 
	 	By: 	/s/Michael S. Anderson
	 	 	Name:  Michael S. Anderson
	 	 	Title:    Chief Executive Officer

 

[Signature Page to the Warrant]

 

    22

     

    

  

EXHIBIT A-1

 

EXERCISE FORM FOR WARRANT

 

TO: [                       ]

 

CHECK THE APPLICABLE BOX: 

  

		 ̈	Cash Exercise or  ̈
                                                                                                                                                    Cashless Exercise

 

The undersigned hereby irrevocably exercises the
attached warrant (the “Warrant”) with respect to _____ American Depositary Shares (“ADSs”) each representing
one Ordinary Share, nominal value $0.01 of Avadel Pharmaceuticals plc, a public limited company incorporated under the laws of
Ireland (the “Company”), and, if pursuant to a Cashless Exercise, herewith makes payment of the Exercise Price with
respect to such shares in full, all in accordance with the conditions and provisions of said Warrant.

 

[IF APPLICABLE: The undersigned hereby encloses $____
as payment of the Exercise Price.]

 

		 ̈	Cashless Major Exercise

 

The undersigned hereby irrevocably exercises the Warrant
with respect to ____% of the Warrant currently outstanding pursuant to a Cashless Major Exercise in accordance with the terms of
the Warrant.

 

		 ̈	Cashless Default Exercise

 

The undersigned hereby irrevocably exercises the
Warrant pursuant to a Cashless Default Exercise, in accordance with the terms of the Warrant.

 

1.          The
undersigned requests that any certificates for such shares be issued free of any restrictive legend, if appropriate, and a warrant
representing any unexercised portion hereof be issued, pursuant to the Warrant in the name of the undersigned and delivered to
the undersigned at the address set forth below.

 

2.          Capitalized
terms used but not otherwise defined in this Exercise Form shall have the meaning ascribed thereto in the Warrant.

 

Dated:                                   

 

	 
	Signature
	 
	 
	Print Name
	 
	 
	Address

 

NOTICE: The signature to the foregoing Exercise Form must correspond
to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change
whatsoever.

 

     

     

    

 

EXHIBIT B

ASSIGNMENT

 

(To be executed by the holder desiring to
transfer the Warrant)

 

FOR VALUE RECEIVED, the undersigned holder of the attached
warrant (the “Warrant”) hereby sells, assigns and transfers in accordance with the terms of the Warrant unto the person
or persons below named the right to purchase, in accordance with the terms of the Warrant, ___________ American Depositary Shares
(“ADSs”) each representing one Ordinary Share, nominal value $0.01 of Avadel Pharmaceuticals plc, a public limited
company incorporated under the laws of Ireland, evidenced by the attached Warrant and does hereby irrevocably constitute and appoint
__________ attorney to transfer the said Warrant on the books of the Company, with full power of substitution in the premises. 

 

	Dated: 		 	 
	 	 	Signature

  

Fill in for new registration of Warrant:

 

	 	 
	Name	 
	 	 
	 	 
	Address	 
	 	 
	 	 
	Please print name and address of assignee 	 
	(including zip code number)	 

 

NOTICE: The signature to the foregoing Assignment must correspond
to the name as written upon the face of the attached Warrant in every particular, without alteration or enlargement or any change
whatsoever.

 

     

     

    

 

EXHIBIT C

 

FORM OF OPINION

 

______, 20__

 

[___________]

 

Re:[                    ] (the “Company”) 

 

Dear Sir:

 

[                  ] (“[                  ]”) intends to transfer
_______ Warrants (the “Warrants”) of the Company to __________ (“_________”) without registration under the Securities Act of 1933, as amended (the “Securities
Act”). In connection therewith, we have examined and relied upon the truth of representations contained in an Investor Representation
Letter attached hereto and have examined such other documents and issues of law as we have deemed relevant.

 

Based on and subject to the foregoing, we are of
the opinion that the transfer of the Warrants by _______ to ______ may be effected without registration under the Securities Act,
provided, however, that the Warrants to be transferred to _______ contain a legend restricting its transferability pursuant to
the Securities Act and that transfer of the Warrants is subject to a stop order.

 

The foregoing opinion is furnished only to____________and
may not be used, circulated, quoted or otherwise referred to or relied upon by you for any purposes other than the purpose for
which furnished or by any other person for any purpose, without our prior written consent.

 

Very truly yours,

 

     

     

    

  

[FORM OF INVESTOR REPRESENTATION
LETTER]

 

_____, 20__

 

[_________________]

 

Gentlemen:

 

___________ (“___”) has agreed to purchase ___________
Warrants (the “Warrants”) of [                        ] (the “Company”) from [                                     ] (“[                 ]”).
We understand that the Warrants are “restricted securities.” We represent and warrant that ______ is a sophisticated
institutional investor that would qualify as an “Accredited Investor” as defined in Rule 501 of Regulation D under
the Securities Act of 1933, as amended (the “Securities Act”).

 

_________ represents and warrants as of the date hereof as follows:

 

1.          That
it is acquiring the Warrants and the American Depositary Shares underlying such Warrants (the “Exercise Shares”) solely
for its account for investment and not with a view to or for sale or distribution of said Warrants or Exercise Shares or any part
thereof in violation of the Securities Act. __________ also represents that the entire legal and beneficial interests of the Warrants
and Exercise Shares __________ is acquiring is being acquired for, and will be held for, its account only;

 

2.          That
the Warrants and the Exercise Shares must be held indefinitely unless they are registered under the Securities Act or an exemption
from such registration is available. __________ recognizes that the Company has no obligation to register the Warrants, or to comply
with any exemption from such registration;

 

3.          That
neither the Warrants nor the Exercise Shares may be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions
are met;

 

We acknowledge that the Company will place stop orders with
respect to the Warrants and the Exercise Shares, and if a registration statement is not effective, the Exercise Shares shall bear
the following restrictive legend:

 

“THE SECURITIES REPRESENTED BY THIS CERTIFICATE
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY
NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION
STATEMENT FOR THE SECURITIES UNDER SAID ACT, OR PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER SAID ACT INCLUDING, WITHOUT LIMITATION,
PURSUANT TO RULES 144 OR 144A UNDER SAID ACT OR PURSUANT TO A PRIVATE SALE EFFECTED UNDER APPLICABLE FORMAL OR INFORMAL SEC INTERPRETATION
OR GUIDANCE, SUCH AS A SO-CALLED “4[(a)](1) AND A HALF” SALE, SUBJECT TO DELIVERY OF AN OPINION, AS PROVIDED IN THE
WARRANT ISSUED AS OF MARCH 13, 2012 BY THE COMPANY.”

 

“THE SALE, TRANSFER, ASSIGNMENT, PLEDGE, HYPOTHECATION
OR OTHER DISPOSITION OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN REGISTRATION
RIGHTS AGREEMENT DATED AS OF MARCH 13, 2012, AS AMENDED FROM TIME TO TIME, AMONG THE COMPANY AND CERTAIN HOLDERS OF ITS OUTSTANDING
SECURITIES. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE
TO THE SECRETARY OF THE COMPANY.”

 

     

     

    

  

At any time and from time to time after the date hereof, __________
shall, without further consideration, execute and deliver to [                         ] or the Company such other instruments or documents
and shall take such other actions as they may reasonably request to carry out the transactions contemplated hereby.

 

Very truly yours,

 

     

     

    

 

Schedule 1 

 

Black-Scholes Value

 

	 	 	Calculation Under Section 5(c)(iii)	 	Calculation Under Section 10(b) or 11(b)
	 	 	 	 	 
	Remaining Term	 	Number of calendar days from date of public announcement of the Major Transaction until the last date on which the Warrant may be exercised.	 	Number of calendar days from date of the determination until the last date on which the Warrant may be exercised.
	 	 	 	 	 
	Interest Rate	 	A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the Remaining Term.	 	A risk-free interest rate corresponding to the US$ LIBOR/Swap rate for a period equal to the Remaining Term.
	 	 	 	 	 
	Volatility	 	
        If the first public announcement of the Major Transaction
        is         made at or prior to 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30
        and 50 Trading Day periods ending on the date of such first public announcement, obtained from the HVT or
        similar function on Bloomberg.

         

        If the first public announcement of the Major Transaction
        is         made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50
        Trading Day periods ending on the next succeeding Trading Day following the date of such first public
        announcement, obtained from the HVT or similar function on Bloomberg.

         

        If the first public announcement of the Major Transaction
        is         made after 4:00 p.m., New York City time, the arithmetic mean of the historical volatility for the 10, 30 and 50
        Trading Day periods ending on the next succeeding Trading Day following the date of such first public
        announcement, obtained from the HVT or similar function on Bloomberg.
	 	The arithmetic mean of the historical volatility for the 10, 30 and 50 Trading Day periods ending on the date of such first public determination, obtained from the HVT or similar function on Bloomberg.
	 	 	 	 	 
	Stock Price	 	The greater of (1) the closing price of the ADSs on NASDAQ, or, if that is not the principal trading market for the ADSs, such principal market on which the ADSs are traded or listed (the “Closing Market Price”) on the trading day immediately preceding the date on which a Major Transaction is consummated, or (2) the first Closing Market Price following the first public announcement of entry into definitive documents for a Major Transaction.	 	The volume Weighted Average Price on the date of such calculation.
	 	 	 	 	 
	Dividends	 	Zero.	 	Zero.
	 	 	 	 	 
	Strike Price	 	Exercise Price as defined in section 3(a).	 	Exercise Price as defined in section 3(a).

 

    2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00265-of-00352.parquet"}]]